BRAF gene mutation assessment is indicated in colorectal cancer, advanced non-small cell lung cancer, melanoma and thyroid cancer. BRAF StripAssays^® identify the most relevant mutations in the BRAF gene.

BRAF

• BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation.
• Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials).
• Testing of patients with metastatic melanoma or advanced non-small cell lung cancer for BRAF V600 mutations prior to treatment is recommended, as BRAF V600 mutation positive patients may benefit from BRAF inhibitor therapy (e.g. dabrafenib, trametinib, vemurafenib).